178 related articles for article (PubMed ID: 21660062)
1. Replication-competent retrovirus vector-mediated prodrug activator gene therapy in experimental models of human malignant mesothelioma.
Kawasaki Y; Tamamoto A; Takagi-Kimura M; Maeyama Y; Yamaoka N; Terada N; Okamura H; Kasahara N; Kubo S
Cancer Gene Ther; 2011 Aug; 18(8):571-8. PubMed ID: 21660062
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic efficacy of replication-competent retrovirus vector-mediated suicide gene therapy in a multifocal colorectal cancer metastasis model.
Hiraoka K; Kimura T; Logg CR; Tai CK; Haga K; Lawson GW; Kasahara N
Cancer Res; 2007 Jun; 67(11):5345-53. PubMed ID: 17545615
[TBL] [Abstract][Full Text] [Related]
3. Highly efficient tumor transduction and antitumor efficacy in experimental human malignant mesothelioma using replicating gibbon ape leukemia virus.
Kubo S; Takagi-Kimura M; Logg CR; Kasahara N
Cancer Gene Ther; 2013 Dec; 20(12):671-7. PubMed ID: 24201868
[TBL] [Abstract][Full Text] [Related]
4. Adenovirus-retrovirus hybrid vectors achieve highly enhanced tumor transduction and antitumor efficacy in vivo.
Kubo S; Haga K; Tamamoto A; Palmer DJ; Ng P; Okamura H; Kasahara N
Mol Ther; 2011 Jan; 19(1):76-82. PubMed ID: 20808291
[TBL] [Abstract][Full Text] [Related]
5. Use of replication-competent retroviral vectors in an immunocompetent intracranial glioma model.
Wang W; Tai CK; Kershaw AD; Solly SK; Klatzmann D; Kasahara N; Chen TC
Neurosurg Focus; 2006 Apr; 20(4):E25. PubMed ID: 16709031
[TBL] [Abstract][Full Text] [Related]
6. Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors.
Kikuchi E; Menendez S; Ozu C; Ohori M; Cordon-Cardo C; Logg CR; Kasahara N; Bochner BH
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4511-8. PubMed ID: 17671137
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Efficacy of Prodrug Activator Gene Therapy Using Retroviral Replicating Vectors for Human Ovarian Cancer.
Isoda L; Sonoda-Fukuda E; Fujino H; Takarada T; Hasegawa K; Kasahara N; Kubo S
Anticancer Res; 2023 Dec; 43(12):5311-5317. PubMed ID: 38030176
[TBL] [Abstract][Full Text] [Related]
8. Efficient Prodrug Activator Gene Therapy by Retroviral Replicating Vectors Prolongs Survival in an Immune-Competent Intracerebral Glioma Model.
Chen SH; Sun JM; Chen BM; Lin SC; Chang HF; Collins S; Chang D; Wu SF; Lu YC; Wang W; Chen TC; Kasahara N; Wang HE; Tai CK
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32093290
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
Akbulut H; Zhang L; Tang Y; Deisseroth A
Cancer Gene Ther; 2003 May; 10(5):388-95. PubMed ID: 12719708
[TBL] [Abstract][Full Text] [Related]
10. Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma.
Tai CK; Wang WJ; Chen TC; Kasahara N
Mol Ther; 2005 Nov; 12(5):842-51. PubMed ID: 16257382
[TBL] [Abstract][Full Text] [Related]
11. Comparative evaluation of preclinical in vivo models for the assessment of replicating retroviral vectors for the treatment of glioblastoma.
Hlavaty J; Jandl G; Liszt M; Petznek H; König-Schuster M; Sedlak J; Egerbacher M; Weissenberger J; Salmons B; Günzburg WH; Renner M
J Neurooncol; 2011 Mar; 102(1):59-69. PubMed ID: 20623247
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic herpes simplex virus expressing yeast cytosine deaminase: relationship between viral replication, transgene expression, prodrug bioactivation.
Yamada S; Kuroda T; Fuchs BC; He X; Supko JG; Schmitt A; McGinn CM; Lanuti M; Tanabe KK
Cancer Gene Ther; 2012 Mar; 19(3):160-70. PubMed ID: 22076044
[TBL] [Abstract][Full Text] [Related]
13. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.
Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R
Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095
[TBL] [Abstract][Full Text] [Related]
14. Highly efficient gene transfer to solid tumors in vivo by tumor-selective replicating retrovirus vectors.
Lu YC; Luo YP; Wang YW; Tai CK
Int J Mol Med; 2010 May; 25(5):769-75. PubMed ID: 20372821
[TBL] [Abstract][Full Text] [Related]
15. Highly efficient and tumor-restricted gene transfer to malignant gliomas by replication-competent retroviral vectors.
Wang WJ; Tai CK; Kasahara N; Chen TC
Hum Gene Ther; 2003 Jan; 14(2):117-27. PubMed ID: 12614563
[TBL] [Abstract][Full Text] [Related]
16. Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model.
Huang TT; Parab S; Burnett R; Diago O; Ostertag D; Hofman FM; Espinoza FL; Martin B; Ibañez CE; Kasahara N; Gruber HE; Pertschuk D; Jolly DJ; Robbins JM
Hum Gene Ther; 2015 Feb; 26(2):82-93. PubMed ID: 25419577
[TBL] [Abstract][Full Text] [Related]
17. Beyond oncolytic virotherapy: replication-competent retrovirus vectors for selective and stable transduction of tumors.
Dalba C; Klatzmann D; Logg CR; Kasahara N
Curr Gene Ther; 2005 Dec; 5(6):655-67. PubMed ID: 16457654
[TBL] [Abstract][Full Text] [Related]
18. Enhanced efficiency of prodrug activation therapy by tumor-selective replicating retrovirus vectors armed with the Escherichia coli purine nucleoside phosphorylase gene.
Tai CK; Wang W; Lai YH; Logg CR; Parker WB; Li YF; Hong JS; Sorscher EJ; Chen TC; Kasahara N
Cancer Gene Ther; 2010 Sep; 17(9):614-23. PubMed ID: 20467451
[TBL] [Abstract][Full Text] [Related]
19. Radiosensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector.
Takahashi M; Valdes G; Hiraoka K; Inagaki A; Kamijima S; Micewicz E; Gruber HE; Robbins JM; Jolly DJ; McBride WH; Iwamoto KS; Kasahara N
Cancer Gene Ther; 2014 Oct; 21(10):405-410. PubMed ID: 25301172
[TBL] [Abstract][Full Text] [Related]
20. Complete regression of human malignant mesothelioma xenografts following local injection of midkine promoter-driven oncolytic adenovirus.
Kubo S; Kawasaki Y; Yamaoka N; Tagawa M; Kasahara N; Terada N; Okamura H
J Gene Med; 2010 Aug; 12(8):681-92. PubMed ID: 20635326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
